JOHANNESBURG - Adcock Ingram Critical Care faces the possibility of a fine following claims by the Competition Commission that its pricing on dialysis products was excessive.
The products are used to help patients who are in kidney failure.
The Competition Commission says the alleged overpricing occurred between 2019 and 2024 and may have involved prices far above production costs.
READ | SPAR cutting jobs as it struggles due to tough competition
It also says the company holds a dominant market position, giving it significant pricing power.
The regulator wants a ruling that the company broke competition law.
This could mean a fine of up to 10% of its turnover.